Latest news with #NEWMEDIAWIRE
Associated Press
3 days ago
- Business
- Associated Press
Innovative Designs Delivers Record Sales Growth and Highest Profitability Level to Date for First 6 Months of 2025 With 265% Increase Year-Over-Year
Superior and Patented Evacuated Cell Insulation Continues to Gain Homebuilding and Remodeling Industry Recognition With Rising Demand PITTSBURGH, PA - June 17, 2025 ( NEWMEDIAWIRE ) - Innovative Designs, Inc. (OTC Pink: IVDN) has filed its financial report for the fiscal second quarter of 2025, ending on April 30th. The Company is pleased to report that continuing revenue growth has pushed the latest results well above previous projections, reaching $796,369 in fiscal Q2 (a 165% increase over fiscal Q2 of 2024). Total revenues for the first 6 months of 2025 reached $1,340,285 (a 265% increase over the total for the same period in 2024). IVDN has now reported profitability for the past three trailing quarters. With this fiscal Q2 filing, the profit level has also increased to a new high for the Company's history with over $240,000 in net income for the first 6 months of 2025 vs. a $41,000 loss at the same point in 2024. About Innovative Designs, Inc. Innovative Designs, Inc. manufactures the Insultex(R) House Wrap and Arctic Armor(R) Line, under the ' label featuring INSULTEX(R). Patented INSULTEX(R) is the thinnest, lightest and warmest insulator in the market today. For more information, please visit: and Disclaimer Certain statements in this press release constitute 'forward-looking' statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the 'Safe Harbor' protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at CONTACT: Innovative Designs, Inc. Joseph A. Riccelli Jr., CEO 412-799-0350 [email protected] Built Link Solutions, LLC Randy Kimbler, Director of Business Development 616-443-3200 [email protected] View the original release on
Associated Press
3 days ago
- Health
- Associated Press
GeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 Meeting
GEO-CM04S1 Demonstrates Superior T Cell Responses Compared to mRNA Vaccine in Phase 2 Trial Among Immunocompromised Patients ATLANTA, GA - June 17, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today highlighted new clinical data presented at the 2025 European Hematology Association (EHA) Hybrid Congress, which took place June 12-15 in Milan, Italy. The data were featured in a poster presentation by Alexey V. Danilov, M.D., Ph.D., Associate Director of the Toni Stephenson Lymphoma Center and Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope Comprehensive Cancer Center in Duarte, California. The poster titled 'MVA-Based GEO-CM04S1 Vaccine Results in Improved Cellular Immune Response in Patients with Chronic Lymphocytic Leukemia (CLL) Compared with mRNA-Based Vaccine: Initial Results of a Phase II Randomized Study', detailed findings from an ongoing randomized Phase 2 clinical trial (NCT05672355), and highlighted interim results showing superior cellular immune responses induced by GEO-CM04S1 compared to those induced by an authorized mRNA-based COVID-19 vaccine in CLL patients, a population known to exhibit suboptimal protective responses to COVID-19 and other vaccines due to immune dysfunction. Key Findings from the Study 'These findings reinforce the clinical and immunologic advantages of our multi-antigen approach,' said Kelly T. McKee, Jr., M.D., Chief Medical Officer of GeoVax. 'GEO-CM04S1's robust cellular response in immunocompromised individuals, especially patients with hematologic malignancies like CLL, provides further validation of our MVA platform's potential to address critical gaps in COVID-19 protection.' About GEO-CM04S1 GEO-CM04S1 is a next-generation COVID-19 vaccine based on a synthetic Modified Vaccinia Ankara (MVA) vector. Unlike single-antigen vaccines, it expresses both the Spike (S) and Nucleocapsid (N) proteins of SARS-CoV-2, aiming to provide broader, cross-reactive, and more durable immunity. The vaccine is currently being evaluated in three Phase 2 clinical trials across various patient populations, including immunocompromised individuals and healthy adults. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: Forward-Looking Statements This release contains forward-looking statements regarding GeoVax's business plans. The words 'believe,' 'look forward to,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventative vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Company Contact: [email protected] 678-384-7220 Investor Relations Contact: [email protected] 212-698-8696 Media Contact: Jessica Starman [email protected]
Yahoo
12-06-2025
- Business
- Yahoo
Healthcare Triangle Secures Major Health System Contracts and Expands AI-Powered EHR Services Nationwide
New Multi-year Wins, Platform Innovation, and AI-driven Growth Strategy Position HCTI for Sustained Growth PLEASANTON, CALIF. - May 28, 2025 (NEWMEDIAWIRE) - Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions including managed services, cloud enablement, and data analytics for the healthcare and life sciences industries today announced approximately $1.0 million of new multi-year strategic contracts wins. These include major agreements with a top-tier university medical system and the largest hospital system on the East Coast. In addition, HCTI is significantly expanding its AI and EHR integration services, reinforcing its position as a trusted innovation partner to health systems nationwide. "These strategic wins reflect our ability to deliver enterprise-scale transformation with speed and precision," said Sujatha Ramesh, Chief Operating Officer of Healthcare Triangle. "We're enabling digital maturity, operational efficiency, and cost-effective care delivery - firmly positioning HCTI as a mission-critical partner, not just a service provider." Aligned with its innovation roadmap, HCTI has also expanded its portfolio with an AI-powered a next-generation AI medical document automation platform that transforms faxes, scanned forms, and unstructured clinical text into structured, actionable data - seamlessly integrating with the electronic health record (EHR). Existing healthcare systems have realized significant benefits by automating their document management processes through The solution has also facilitated the transformation of unstructured clinical text into structured, actionable data - seamlessly integrating with electronic health records (EHR) to enhance clinical decision-making and operational efficiency "These wins and platform advancements are accelerating our shift to a recurring revenue model," added David Ayanoglou, Chief Financial Officer of HCTI. "We're delivering scalable, AI-powered solutions that improve margins, expand our footprint, and increase enterprise value. HCTI is well-positioned for long-term growth and profitability." Further strengthening its community focus, HCTI is exploring high-impact EPIC workflow integrations tailored to community health system deployments. These efforts aim to enhance clinical efficiency, streamline onboarding, and bring enterprise-grade performance to underserved and regional networks - delivering scalable solutions at lower cost. With a growing portfolio of strategic contracts, breakthrough AI platforms, and an expanding presence across enterprise and community health systems, HCTI is charting a clear path towards sustainable, technology-driven growth. The Company remains focused on delivering innovation at scale and unlocking long-term value for clients, partners, and shareholders. HCTI maintains strategic partnerships with leading public cloud providers - Amazon Web Services (AWS), Google Cloud Platform (GCP), and Microsoft Azure. About Healthcare Triangle Healthcare Triangle, Inc. based in Pleasanton, California, reinforces healthcare progress through breakthrough technology and extensive industry knowledge and expertise. We support healthcare including hospitals and health systems, payers, and pharma/life sciences organizations in their effort to improve health outcomes through better utilization of the data and information technologies that they rely on. Healthcare Triangle achieves HITRUST Certification for Cloud and Data Platform (CaDP), marketed as CloudEz(TM) and DataEz(TM). HITRUST Risk-based, 2-year (r2) Certified status demonstrates to our clients the highest standards for data protection and information security. Healthcare Triangle enables the adoption of new technologies, data enlightenment, business agility, and response to immediate business needs and competitive threats. The highly regulated healthcare and life sciences industries rely on Healthcare Triangle for expertise in digital transformation encompassing the cloud, security and compliance, data lifecycle management, healthcare interoperability, and clinical and business performance optimization. Forward-Looking Statements and Safe Harbor Notice All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995), and include, among others, statements regarding the consummation of the private placement, satisfaction of the customary closing conditions of the private placement and the use of the proceeds therefrom. Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions, including market and other conditions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, on file with the Securities Exchange Commission (the "SEC") and in previous filings, subsequent filings and future periodic reports filed with the SEC. All the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. Investors:1-800-617-9550ir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-06-2025
- Business
- Yahoo
GeoVax to Participate in BIO International Convention 2025
ATLANTA, GA - June 12, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today announced that company representatives will attend the 2025 BIO International Convention being held June 16-19, 2025 at the Boston Convention and Exhibition Center in Boston, Massachusetts. The BIO International Convention is the world's largest gathering of the biotechnology industry, attracting thousands of biotechnology and pharmaceutical executives from around the globe. The event provides an ideal venue for companies to engage with potential partners, investors, and policymakers. During the convention, GeoVax will participate in business development and partnering meetings to discuss its expanding pipeline of infectious disease and cancer immunotherapies, including GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting Mpox and smallpox; GEO-CM04S1, a multi-antigen COVID-19 vaccine candidate; and Gedeptin(R), a gene-directed enzyme prodrug therapy for the treatment of solid tumors. GeoVax's participation at BIO 2025 supports its broader business development strategy, including ongoing efforts to establish strategic partnerships, expand manufacturing capabilities, and align with public and private sector priorities in pandemic preparedness, oncology, and biodefense. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: Company Contact:info@ Investor Relationsgeovax@ Contact: Media Contact:Jessica Starmanmedia@ View the original release on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
12-06-2025
- Business
- Associated Press
New Book On Board Equips Corporate Boards to Navigate Governance in a Changing Business Climate
NEW YORK, NY - June 11, 2025 ( NEWMEDIAWIRE ) - Corporate governance faces increased scrutiny amid economic uncertainty and evolving expectations. Corporate board members and executives now have a unique resource: On Board: The Modern Playbook for Corporate Governance, by governance expert Jon Foster. This vital guide provides a readable historical perspective on how we got to now with a contemporary history of transactions (mergers and acquisitions, LBOs, activism, and restructurings), the growing importance of institutional investors, and the rise and now waning of environmental, social, and governance (ESG) issues that provide context for today's laws, standards, and best practices for good governance. Then, with experience, stories, and anecdotes from inside boardrooms, courtrooms, and investor meetings, Foster provides critical insights on the key issues that boards face. These include recruiting and onboarding directors, overseeing but not managing the company, board leadership, board committees, interacting effectively with the CEO, seeing that there are plans to mitigate risks and handle crises, and whether the board should target the maximization of shareholder or stakeholder value. This timely book, which addresses the dynamic landscape of governance and leadership, equips readers with the knowledge they need to navigate today's complex business environment. With experience on over 50 corporate boards, an expert witness on governance, mergers and acquisitions, restructurings and other topics in some 60 cases, and more than three decades as an investment banker, Foster offers informed views on board oversight, fiduciary responsibilities, management, shareholder engagement, and emerging governance challenges. This book provides a practical and straightforward approach to building and sustaining high-functioning boards that promote long-term success while managing risks and addressing shareholder expectations. 'As corporate governance evolves, it becomes increasingly critical for boards to clearly understand and address effectively their responsibilities and stay ahead of emerging trends,' Foster explains. 'On Board is a modern playbook for directors, offering actionable guidance rooted in lessons from the past, real-world experience, and anticipation of what may come next.' Key Themes in On Board: About Jonathan F. Foster is a deeply experienced corporate director, investment banker, and expert witness in corporate litigation. He has been on over 50 boards of directors of Fortune 500 companies, private equity firm portfolio companies, private companies, and distressed companies. He has served as a non-executive chairman, audit committee chair, and member of numerous board committees. Foster founded and is managing partner of Current Capital Partners, an advisory and merchant banking firm. Media Contact Full Name: Kathleen Schmidt Title: Founder Company Name: KMSPR Email: [email protected] Phone Number: 19734777091 Website:
